Short native antimicrobial peptides and engineered ultrashort lipopeptides: Similarities and differences in cell specificities and modes of action

Cellular and Molecular Life Sciences

Volumn 68, Issue 13, 2011, Pages 2267-2280

  Mangoni, Maria Luisa ^a   Shai, Yechiel ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Antimicrobial peptides; Cell selectivity; Lipopeptides; LPS neutralizing activity; Mode of action; Peptide membrane interaction

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; C14 LYSYLLEUCYLLEUCYLLYSINE; C16 LYSYLALANYLALANYLLYSINE; C16 LYSYLALANYLLYSINE; C16 LYSYLGLYCYLGLYCYLLYSINE; C16 LYSYLLYSINE; C16 LYSYLLYSYLLYSINE; C16 LYSYLLYSYLLYSYLLYSINE; DAPTOMYCIN; DERMASEPTIN; HISTIDINYLPHENYLALANYLLEUCYLGLYCYLTHREONYLLEUCYLVALYLASPARAGINYLLEUCYLALANYLLYSYLLYSYLISOLEUCYLLYSINE AMIDE; LIPOPEPTIDE; PHENYLALANYLLEUCYLPROLYLISOLEUCYLISOLEUCYLALANYLLYSYLVALYLLEUCYLSERYLGLYCYLLEUCYLLEUCINE AMIDE; PHENYLALANYLLEUCYLPROLYLISOLEUCYLISOLEUCYLGLYCYLGLUTAMINYLLEUCYLLEUCYLSERYLGLYCYLLEUCYLLEUCINE AMIDE; PHENYLALANYLLEUCYLPROLYLISOLEUCYLVALYLGLYCYLARGINYLLEUCYLSERYLGLYCYLLEUCYLLEUCINE AMIDE; PHENYLALANYLLEUCYLPROLYLISOLEUCYLVALYLGLYCYLLYSYLLEUCYLLEUCYLSERYLGLYCYLLEUCYLLEUCINE AMIDE; PHENYLALANYLLEUCYLPROLYLISOLEUCYLVALYLGLYCYLLYSYLLYSYLSERYLGLYCYLLEUCYLLEUCINE AMIDE; PHENYLALANYLLEUCYLPROLYLLEUCYLLEUCYLALANYLSERYLLEUCYLPHENYLALANYLSERYLARGINYLLEUCYLLEUCINE AMIDE; PHENYLALANYLLEUCYLPROLYLLEUCYLLEUCYLPHENYLALANYLGLYCYLALANYLISOLEUCYLHISTIDINYLLEUCYLLEUCINE AMIDE; PHENYLALANYLLEUCYLPROLYLPHENYLALANYLLEUCYLALANYLLYSYLISOLEUCYLTHREONYLGLYCYLVALYLLEUCINE AMIDE; PHENYLALANYLLEUCYLPROLYLPHENYLALANYLLEUCYLLYSYLSERYLISOLEUCYLLEUCYLGLYCYLLYSYLISOLEUCYLLYSINE AMIDE; PHENYLALANYLLEUCYLPROLYLVALYLISOLEUCYLALANYLGLYCYLLEUCYLLEUCYLSERYLLYSYLLEUCYLPHENYLALANINE AMIDE; PHENYLALANYLLEUCYLSERYLALANYLISOLEUCYLTHREONYLSERYLISOLEUCYLLEUCINEGLYCYLLYSYLPHENYLALANYLPHENYLALANINE AMIDE; PHENYLALANYLPHENYLALANYLPHENYLALANYLLEUCYLSERYLARGINYLISOLEUCYLPHENYLALANINE AMIDE; POLYPEPTIDE ANTIBIOTIC AGENT; SERYLISOLEUCYLPHENYLALANYLPROLYLALANYLISOLEUCYLVALYLSERYLPHENYLALANYLLEUCYLSERYLLYSYLPHENYLALANYLLYSINE AMIDE; SERYLISOLEUCYLPROLYLTHREONYLISOLEUCYLVALYLSERYLPHENYLALANYLLEUCYLSERYLLYSYLVALYLPHENYLALANINE AMIDE; TEMPORIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALYLLEUCYLPROLYLLEUCYLISOLEUCYLSERYLMETHIONYLALANYLLEUCYLGLYCYLLYSYLLEUCYLLEUCINE AMIDE;

ACYLATION; ALPHA HELIX; AMASTIGOTE; AUTOPHAGY; BACTERIAL CELL WALL; BACTERIAL OUTER MEMBRANE; BETA SHEET; CANDIDIASIS; CELL KILLING; CELL SPECIFICITY; DRUG ACTIVITY; DRUG CONFORMATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HYDROPHOBICITY; IMMUNOMODULATION; LIPID VESICLE; LIPOPHILICITY; MEMBRANE TRANSPORT; MINIMUM INHIBITORY CONCENTRATION; PHOSPHOLIPID MEMBRANE; PROTEIN DEGRADATION; REVIEW; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCUS INFECTION;

ACYLATION; AMINO ACID SEQUENCE; ANTIMICROBIAL CATIONIC PEPTIDES; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG DESIGN; FATTY ACIDS; HUMANS; LIPOPEPTIDES; MEMBRANE LIPIDS; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; PROTEINS;

AMPHIBIA;

EID: 79960934532     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-011-0718-2     Document Type: Review

References (160)

1. Boman HG (2003) Antibacterial peptides: basic facts and emerging concepts. J Intern Med 254:197-215
2. Boman HG (1995) Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 13:61-92
3. Ganz T, Lehrer RI (1998) Antimicrobial peptides of vertebrates. Curr Opin Immunol 10:41-44 (Pubitemid 28112077)
4. Hancock REW, Brown KL, Mookherjee N (2006) Host defence peptides from invertebrates - emerging antimicrobial strategies. Immunobiology 211:315-322
5. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415:389-395
6. Selsted ME, Ouellette AJ (2005) Mammalian defensins in the antimicrobial immune response. Nat Immunol 6:551-557 (Pubitemid 41710724)
7. Peters BM, Shirtliff ME, Jabra-Rizk MA (2010) Antimicrobial peptides: primeval molecules or future drugs? PLoS Pathog 6:e1001067
8. Steinstraesser L, Kraneburg U, Jacobsen F, Al-Benna S (2011) Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology 216:322-333
9. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, Hultgren SJ, Matrisian LM, Parks WC (1999) Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 286:113-117 (Pubitemid 29484488)
10. Lehrer RI, Ganz T (2002) Cathelicidins: a family of endogenous antimicrobial peptides. Curr Opin Hematol 9:18-22 (Pubitemid 34025307)
11. Ganz T (2005) Defensins and other antimicrobial peptides: a historical perspective and an update. Comb Chem High Throughput Screen 8:209-217
12. Steiner H, Hultmark D, Engstrom A, Bennich H, Boman HG (1981) Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 292:246-248 (Pubitemid 11001840)
13. Zasloff M (1987) Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 84:5449-5453
14. Hancock REW (2001) Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1:156-164
15. Sahl HG, Pag U, Bonness S, Wagner S, Antcheva N, Tossi A (2005) Mammalian defensins: structures and mechanism of antibiotic activity. J Leukoc Biol 77:466-475 (Pubitemid 40489522)
16. Osterholm MT (1996) Emerging infectious diseases. A real public health crisis? Postgrad Med 100:15-16, 21, 25-26
17. Maviglia R, Nestorini R, Pennisi M (2009) Role of old antibiotics in multidrug resistant bacterial infections. Curr Drug Targets 10:895-905
18. Denning DW (1997) Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. J Antimicrob Chemother 40:611-614
19. Denning DW (2002) Echinocandins: a new class of antifungal. J Antimicrob Chemother 49:889-891
20. Straus SK, Hancock REW (2006) Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta 1758:1215-1223 (Pubitemid 44436068)
21. Balkovec JM (1994) Anti-infectives: lipopeptide antifungal agents. Expert Opin Invest Drugs 3:65-82
22. De Lucca AJ, Walsh TJ (1999) Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother 43:1-11 (Pubitemid 29069190)
23. Bassarello C, Lazzaroni S, Bifulco G, Lo Cantore P, Iacobellis NS, Riccio R, Gomez-Paloma L, Evidente A (2004) Tolaasins A-E, five new lipodepsipeptides produced by Pseudomonas tolaasii. J Nat Prod 67:811-816 (Pubitemid 38702737)
24. Peggion C, Formaggio F, Crisma M, Epand RF, Epand RM, Toniolo C (2003) Trichogin: a paradigm for lipopeptaibols. J Pept Sci 9:679-689 (Pubitemid 37493353)
25. Tsubery H, Ofek I, Cohen S, Fridkin M (2001) N-terminal modifications of polymyxin B nonapeptide and their effect on antibacterial activity. Peptides 22:1675-1681 (Pubitemid 32918247)
26. Fiechter A (1992) Biosurfactants: moving towards industrial application. Trends Biotechnol 10:208-217
27. Raaijmakers JM, de Bruijn I, de Kock MJ (2006) Cyclic lipopeptide production by plant-associated Pseudomonas spp.: diversity, activity, biosynthesis, and regulation. Mol Plant Microbe Interact 19:699-710
28. Jeu L, Fung HB (2004) Daptomycin: a cyclic lipopeptide antimicrobial agent. Clin Ther 26:1728-1757 (Pubitemid 40089488)
29. Sauermann R, Rothenburger M, Graninger W, Joukhadar C (2008) Daptomycin: a review 4 years after first approval. Pharmacology 81:79-91 (Pubitemid 351182681)
30. Moudgal V, Little T, Boikov D, Vazquez JA (2005) Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49:767-769 (Pubitemid 40175691)
31. Avrahami D, Shai Y (2002) Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity. Biochemistry 41:2254-2263 (Pubitemid 34160886)
32. Chicharro C, Granata C, Lozano R, Andreu D, Rivas L (2001) N-terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a cecropin-melittin hybrid peptide. Antimicrob Agents Chemother 45:2441-2449
33. Lockwood NA, Haseman JR, Tirrell MV, Mayo KH (2004) Acylation of SC4 dodecapeptide increases bactericidal potency against Gram-positive bacteria, including drug-resistant strains. Biochem J 378:93-103 (Pubitemid 38299547)
34. Majerle A, Kidric J, Jerala R (2003) Enhancement of antibacterial and lipopolysaccharide binding activities of a human lactoferrin peptide fragment by the addition of acyl chain. J Antimicrob Chemother 51:1159-1165 (Pubitemid 36622072)
35. Mak P, Pohl J, Dubin A, Reed MS, Bowers SE, Fallon MT, Shafer WM (2003) The increased bactericidal activity of a fatty acid-modified synthetic antimicrobial peptide of human cathepsin G correlates with its enhanced capacity to interact with model membranes. Int J Antimicrob Agents 21:13-19 (Pubitemid 36043970)
36. Radzishevsky IS, Rotem S, Zaknoon F, Gaidukov L, Dagan A, Mor A (2005) Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides. Antimicrob Agents Chemother 49:2412-2420 (Pubitemid 40734474)
37. Wakabayashi H, Matsumoto H, Hashimoto K, Teraguchi S, Takase M, Hayasawa H (1999) N-Acylated and D enantiomer derivatives of a nonamer core peptide of lactoferricin B showing improved antimicrobial activity. Antimicrob Agents Chemother 43:1267-1269 (Pubitemid 29214760)
38. Avrahami D, Shai Y (2003) Bestowing antifungal and antibacterial activities by lipophilic acid conjugation to D, L-amino acid-containing antimicrobial peptides: a plausible mode of action. Biochemistry 42:14946-14956
39. Avrahami D, Shai Y (2004) A new group of antifungal and antibacterial lipopeptides derived fromnon-membrane active peptides conjugated to palmitic acid. J Biol Chem 279:12277-12285 (Pubitemid 38445793)
40. Malina A, Shai Y (2005) Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem J 390:695-702 (Pubitemid 41395352)
41. Mookherjee N, Hancock REW (2007) Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci 64:922-933 (Pubitemid 46597762)
42. Maget-Dana R, Peypoux F (1994) Iturins, a special class of pore-forming lipopeptides: biological and physicochemical properties. Toxicology 87:151-174
43. Maget-Dana R, Ptak M (1995) Interactions of surfactin with membrane models. Biophys J 68:1937-1943
44. Peypoux F, Bonmatin JM, Wallach J (1999) Recent trends in the biochemistry of surfactin. Appl Microbiol Biotechnol 51:553-563 (Pubitemid 29266305)
45. Steenbergen JN, Alder J, Thorne GM, Tally FP (2005) Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55:283-288 (Pubitemid 40425449)
46. Simmaco M, Mignogna G, Barra D (1998) Antimicrobial peptides from amphibian skin: what do they tell us? Biopolymers 47:435-450
47. Rinaldi AC (2002) Antimicrobial peptides from amphibian skin: an expanding scenario. Curr Opin Chem Biol 6:799-804
48. Conlon JM, Iwamuro S, King JD (2009) Dermal cytolytic peptides and the system of innate immunity in anurans. Ann NY Acad Sci 1163:75-82
49. Miele R, Ponti D, Boman HG, Barra D, Simmaco M (1998) Molecular cloning of a bombinin gene from Bombina orientalis: detection of NF-kappaB and NF-IL6 binding sites in its promoter. FEBS Lett 431:23-28 (Pubitemid 28330845)
50. Simmaco M, Mignogna G, Canofeni S, Miele R, Mangoni ML, Barra D (1996) Temporins, antimicrobial peptides from the European red frog Rana temporaria. Eur J Biochem 242:788-792 (Pubitemid 27121165)
51. Mangoni ML (2006) Temporins, anti-infective peptides with expanding properties. Cell Mol Life Sci 63:1060-1069
52. Mangoni ML, Shai Y (2009) Temporins and their synergism against Gram-negative bacteria and in lipopolysaccharide detoxification. Biochim Biophys Acta 1788:1610-1619
53. Rinaldi AC, Mangoni ML, Rufo A, Luzi C, Barra D, Zhao H, Kinnunen PK, Bozzi A, Di Giulio A, Simmaco M (2002) Temporin L: antimicrobial, haemolytic and cytotoxic activities, and effects on membrane permeabilization in lipid vesicles. Biochem J 368:91-100 (Pubitemid 35463412)
54. Zhao H, Kinnunen PK (2003) Modulation of the activity of secretory phospholipase A2 by antimicrobial peptides. Antimicrob Agents Chemother 47:965-971 (Pubitemid 36254222)
55. Abbassi F, Lequin O, Piesse C, Goasdoue N, Foulon T, Nicolas P, Ladram A (2010) Temporin-SHf, a new type of phe-rich and hydrophobic ultrashort antimicrobial peptide. J Biol Chem 285:16880-16892
56. Makovitzki A, Avrahami D, Shai Y (2006) Ultrashort antibacterial and antifungal lipopeptides. Proc Natl Acad Sci USA 103:15997-16002 (Pubitemid 44657581)
57. Makovitzki A, Baram J, Shai Y (2008) Antimicrobial lipopolypeptides composed of palmitoyl di- and tricationic peptides: in vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. Biochemistry 47:10630-10636
58. Shai Y, Makovitzky A, Avrahami D (2006) Host defense peptides and lipopeptides: modes of action and potential candidates for the treatment of bacterial and fungal infections. Curr Protein Pept Sci 7:479-486 (Pubitemid 44883925)
59. Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y (1999) Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem J 341:501-513 (Pubitemid 29389178)
60. Papo N, Braunstein A, Eshhar Z, Shai Y (2004) Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino acid peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res 64:5779-5786 (Pubitemid 39095578)
61. Papo N, Oren Z, Pag U, Sahl HG, Shai Y (2002) The consequence of sequence alteration of an amphipathic alpha-helical antimicrobial peptide and its diastereomers. J Biol Chem 277:33913-33921
62. Papo N, Seger D, Makovitzki A, Kalchenko V, Eshhar Z, Degani H, Shai Y (2006) Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res 66:5371-5378 (Pubitemid 43844963)
63. Radzishevsky IS, Rotem S, Bourdetsky D, Navon-Venezia S, Carmeli Y, Mor A (2007) Improved antimicrobial peptides based on acyl-lysine oligomers. Nat Biotechnol 25:657-659 (Pubitemid 46897206)
64. Rotem S, Radzishevsky IS, Bourdetsky D, Navon-Venezia S, Carmeli Y, Mor A (2008) Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. FASEB J 22:2652-2661
65. Sarig H, Rotem S, Ziserman L, Danino D, Mor A (2008) Impact of self-assembly properties on antibacterial activity of short acyl-lysine oligomers. Antimicrob Agents Chemother 52:4308-4314
66. Lehrer RI, Ganz T (1999) Antimicrobial peptides in mammalian and insect host defence. Curr Opin Immunol 11:23-27 (Pubitemid 29082332)
67. Shai Y (2002) From innate immunity to de novo designed antimicrobial peptides. Curr Pharm Des 8:715-725
68. Marcellini L, Borro M, Gentile G, Rinaldi AC, Stella L, Aimola P, Barra D, Mangoni ML (2009) Esculentin-1b(1-18)-a membrane-active antimicrobial peptide that synergizes with antibiotics and modifies the expression level of a limited number of proteins in Escherichia coli. FEBS J 276:5647-5664
69. Coccia C, Rinaldi AC, Luca V, Barra D, Bozzi A, Di Giulio A, Veerman EC, Mangoni ML (2011) Membrane interaction and antibacterial properties of two mildly cationic peptide diastereomers, bombinins H2 and H4, isolated from Bombina skin. Eur Biophys J 40(4):577-588
70. Hancock REW, Diamond G (2000) The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 8:402-410
71. Patrzykat A, Friedrich CL, Zhang L, Mendoza V, Hancock REW (2002) Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob Agents Chemother 46:605-614 (Pubitemid 34162506)
72. Subbalakshmi C, Sitaram N (1998) Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett 160:91-96 (Pubitemid 28098557)
73. Chen W, Wang J, An H, Zhou J, Zhang L, Cao X (2005) Heat shock up-regulates TLR9 expression in human B cells through activation of ERK and NF-kappaB signal pathways. Immunol Lett 98:153-159 (Pubitemid 40409831)
74. Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV, Weinberg A, Sieg SF (2007) Human-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA 104:18631-18635 (Pubitemid 350210748)
75. Wu H, Arron JR (2003) TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays 25:1096-1105 (Pubitemid 37411769)
76. Brogden KA (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3:238-250
77. Nicholls EF, Madera L, Hancock RE (2010) Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann NY Acad Sci 1213:46-61
78. Rosenfeld Y, Sahl HG, Shai Y (2008) Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides. Biochemistry 47:6468-6478 (Pubitemid 351874238)
79. Bechinger B, Lohner K (2006) Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochim Biophys Acta 1758:1529-1539 (Pubitemid 44436087)
80. Lohner K (2009) New strategies for novel antibiotics: peptides targeting bacterial cell membranes. Gen Physiol Biophys 28:105-116
81. Wassef MK, Fioretti TB, Dwyer DM (1985) Lipid analyses of isolated surface membranes of Leishmania donovani promastigotes. Lipids 20:108-115
82. Ehrenstein G, Lecar H (1977) Electrically gated ionic channels in lipid bilayers. Q Rev Biophys 10:1-34 (Pubitemid 8065109)
83. Shai Y (2002) Mode of action of membrane active antimicrobial peptides. Biopolymers 66:236-248
84. Ludtke SJ, He K, Heller WT, Harroun TA, Yang L, Huang HW (1996) Membrane pores induced by magainin. Biochemistry 35:13723-13728 (Pubitemid 26363914)
85. Matsuzaki K, Murase O, Miyajima K (1995) Kinetics of pore formation by an antimicrobial peptide, magainin 2, in phospholipid bilayers. Biochemistry 34:12553-12559
86. Hancock REW, Rozek A (2002) Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol Lett 206:143-149 (Pubitemid 34117610)
87. Mangoni ML, Papo N, Barra D, Simmaco M, Bozzi A, Di Giulio A, Rinaldi AC (2004) Effects of the antimicrobial peptide temporin L on cell morphology, membrane permeability and viability of Escherichia coli. Biochem J 380:859-865 (Pubitemid 38850528)
88. Steffen H, Rieg S, Wiedemann I, Kalbacher H, Deeg M, Sahl HG, Peschel A, Gotz F, Garbe C, Schittek B (2006) Naturally processed dermcidin-derived peptides do not permeabilize bacterial membranes and kill microorganisms irrespective of their charge. Antimicrob Agents Chemother 50:2608-2620 (Pubitemid 44198678)
89. Bera A, Singh S, Nagaraj R, Vaidya T (2003) Induction of autophagic cell death in Leishmania donovani by antimicrobial peptides. Mol Biochem Parasitol 127:23-35 (Pubitemid 36263230)
90. Georgopapadakou NH, Tkacz JS (1995) The fungal cell wall as a drug target. Trends Microbiol 3:98-104
91. Kartsonis NA, Nielsen J, Douglas CM (2003) Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 6:197-218 (Pubitemid 37129919)
92. Ullmann AJ (2003) Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 19:263-271
93. Debono M, Gordee RS (1994) Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 48:471-497 (Pubitemid 24334106)
94. Evans ME, Feola DJ, Rapp RP (1999) Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 33:960-967 (Pubitemid 29420995)
95. Toniolo C, Crisma M, Formaggio F, Peggion C, Epand RF, Epand RM (2001) Lipopeptaibols, a novel family of membrane active, antimicrobial peptides. Cell Mol Life Sci 58:1179-1188 (Pubitemid 32844092)
96. Alexander C, Rietschel ET (2001) Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 7:167-202 (Pubitemid 32894573)
97. Raetz CR, Whitfield C (2002) Lipopolysaccharide endotoxins. Annu Rev Biochem 71:635-700 (Pubitemid 34800232)
98. Nikaido H (1994) Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264:382-388
99. Nikaido H, Vaara M (1985) Molecular basis of bacterial outer membrane permeability. Microbiol Rev 49:1-32 (Pubitemid 15134118)
100. Rosenfeld Y, Barra D, Simmaco M, Shai Y, Mangoni ML (2006) A synergism between temporins toward Gram-negative bacteria overcomes resistance imposed by the lipopolysaccharide protective layer. J Biol Chem 281:28565-28574 (Pubitemid 44506999)
101. Papo N, Shai Y (2005) A molecular mechanism for lipopolysaccharide protection of Gram-negative bacteria from antimicrobial peptides. J Biol Chem 280:10378-10387 (Pubitemid 40395894)
102. Sal-Man N, Oren Z, Shai Y (2002) Preassembly of membrane-active peptides is an important factor in their selectivity toward target cells. Biochemistry 41:11921-11930
103. Trent MS, Stead CM, Tran AX, Hankins JV (2006) Diversity of endotoxin and its impact on pathogenesis. J Endotoxin Res 12:205-223 (Pubitemid 47470164)
104. Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow H, Ulmer AJ, Zahringer U, Seydel U, Di Padova F, Schreier M, Brade H (1994) Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 8:217-225 (Pubitemid 24067145)
105. Nikaido H (1989) Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 33:1831-1836
106. Friedrich CL, Moyles D, Beveridge TJ, Hancock REW (2000) Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria. Antimicrob Agents Chemother 44:2086-2092 (Pubitemid 30484431)
107. Papo N, Shai Y (2005) Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 62:784-790 (Pubitemid 40655628)
108. Allende D, McIntosh TJ (2003) Lipopolysaccharides in bacterial membranes act like cholesterol in eukaryotic plasma membranes in providing protection against melittin-induced bilayer lysis. Biochemistry 42:1101-1108 (Pubitemid 36159545)
109. Andra J, Koch MH, Bartels R, Brandenburg K (2004) Biophysical characterization of endotoxin inactivation by NK-2, an antimicrobial peptide derived from mammalian NK-lysin. Antimicrob Agents Chemother 48:1593-1599 (Pubitemid 38544364)
110. Mangoni ML, Rinaldi AC, Di Giulio A, Mignogna G, Bozzi A, Barra D, Simmaco M (2000) Structure-function relationships of temporins, small antimicrobial peptides from amphibian skin. Eur J Biochem 267:1447-1454 (Pubitemid 30143284)
111. Makovitzki A, Shai Y (2005) pH-dependent antifungal lipopeptides and their plausible mode of action. Biochemistry 44:9775-9784 (Pubitemid 40994371)
112. Domanov YA, Kinnunen PK (2006) Antimicrobial peptides temporins B and L induce formation of tubular lipid protrusions from supported phospholipid bilayers. Biophys J 91:4427-4439 (Pubitemid 44904229)
113. Mahalka AK, Kinnunen PK (2009) Binding of amphipathic alpha-helical antimicrobial peptides to lipid membranes: lessons from temporins B and L. Biochim Biophys Acta 1788:1600-1609
114. Turco SJ, Hull SR, Orlandi PA, Shepherd SD, Homans SW, Dwek RA, Rademacher TW (1987) Structure of the major carbohydrate fragment of the Leishmania donovani lipophosphoglycan. Biochemistry 26:6233-6238
115. McConville MJ, Mullin KA, Ilgoutz SC, Teasdale RD (2002) Secretory pathway of trypanosomatid parasites. Microbiol Mol Biol Rev 66:122-154 (Pubitemid 34213971)
116. Mangoni ML, Saugar JM, Dellisanti M, Barra D, Simmaco M, Rivas L (2005) Temporins, small antimicrobial peptides with leishmanicidal activity. J Biol Chem 280:984-990
117. Mor A, Hani K, Nicolas P (1994) The vertebrate peptide antibiotics dermaseptins have overlapping structural features but target specific microorganisms. J Biol Chem 269:31635-31641 (Pubitemid 24379527)
118. Mangoni ML, Epand RF, Rosenfeld Y, Peleg A, Barra D, Epand RM, Shai Y (2008) Lipopolysaccharide, a key molecule involved in the synergism between temporins in inhibiting bacterial growth and in endotoxin neutralization. J Biol Chem 283:22907-22917
119. Giacometti A, Cirioni O, Ghiselli R, Mocchegiani F, Orlando F, Silvestri C, Bozzi A, Di Giulio A, Luzi C, Mangoni ML, Barra D, Saba V, Scalise G, Rinaldi AC (2006) Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria. Antimicrob Agents Chemother 50:2478-2486 (Pubitemid 43993189)
120. Kubo Y, Fukuishi N, Yoshioka M, Kawasoe Y, Iriguchi S, Imajo N, Yasui Y, Matsui N, Akagi M (2007) Bacterial components regulate the expression of Toll-like receptor 4 on human mast cells. Inflamm Res 56:70-75 (Pubitemid 46412011)
121. Gee K, Kozlowski M, Kumar A (2003) Tumor necrosis factor-alpha induces functionally active hyaluronan-adhesive CD44 by activating sialidase through p38 mitogen-activated protein kinase in lipopolysaccharide-stimulated human monocytic cells. J Biol Chem 278:37275-37287 (Pubitemid 37175244)
122. Mukhopadhyay S, Herre J, Brown GD, Gordon S (2004) The potential for Toll-like receptors to collaborate with other innate immune receptors. Immunology 112:521-530 (Pubitemid 39061476)
123. Prins JM, Kuijper EJ, Mevissen ML, Speelman P, van Deventer SJ (1995) Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 63:2236-2242
124. Byl B, Clevenbergh P, Kentos A, Jacobs F, Marchant A, Vincent JL, Thys JP (2001) Ceftazidime and imipenem-induced endotoxin release during treatment of gram-negative infections. Eur J Clin Microbiol Infect Dis 20:804-807 (Pubitemid 34020457)
125. Cohen J (2002) The immunopathogenesis of sepsis. Nature 420:885-891
126. Angus DC, Wax RS (2001) Epidemiology of sepsis: an update. Crit Care Med 29:S109-S116 (Pubitemid 32681592)
127. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock REW (2002) The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 169:3883-3891
128. Bommineni YR, Dai H, Gong YX, Soulages JL, Fernando SC, Desilva U, Prakash O, Zhang G (2007) Fowlicidin-3 is an alphahelical cationic host defense peptide with potent antibacterial and lipopolysaccharide-neutralizing activities. FEBS J 274:418-428 (Pubitemid 46046651)
129. Mookherjee N, Rehaume LM, Hancock RE (2007) Cathelicidins and functional analogues as antisepsis molecules. Expert Opin Ther Targets 11:993-1004 (Pubitemid 47240677)
130. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433
131. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ (1990) Structure and function of lipopolysaccharide binding protein. Science 249:1429-1431 (Pubitemid 120034117)
132. Tobias PS, Ulevitch RJ (1993) Lipopolysaccharide binding protein and CD14 in LPS dependent macrophage activation. Immunobiology 187:227-232 (Pubitemid 23150769)
133. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088 (Pubitemid 29001265)
134. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F (1999) Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274:10689-10692
135. Jiang Q, Akashi S, Miyake K, Petty HR (2000) Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. J Immunol 165:3541-3544 (Pubitemid 32057253)
136. Rosenfeld Y, Lev N, Shai Y (2010) Effect of the hydrophobicity to net positive charge ratio on antibacterial and anti-endotoxin activities of structurally similar antimicrobial peptides. Biochemistry 49:361-853
137. Uccelletti D, Zanni E, Marcellini L, Palleschi C, Barra D, Mangoni ML (2010) Anti-Pseudomonas activity of frog skin antimicrobial peptides in a Caenorhabditis elegans infection model: a plausible mode of action in vitro and in vivo. Antimicrob Agents Chemother 54:3853-3860
138. Vallon-Eberhard A, Landsman L, Yogev N, Verrier B, Jung S (2006) Transepithelial pathogen uptake into the small intestinal lamina propria. J Immunol 176:2465-2469 (Pubitemid 43201697)
139. Lopez-Garcia B, Lee PH, Yamasaki K, Gallo RL (2005) Antifungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 125:108-115 (Pubitemid 40981431)
140. Buentke E, Scheynius A (2003) Dendritic cells and fungi. APMIS 111:789-796 (Pubitemid 37130025)
141. Van Burik JA, Magee PT (2001) Aspects of fungal pathogenesis in humans. Annu Rev Microbiol 55:743-772
142. Netea MG, Brown GD, Kullberg BJ, Gow NA (2008) An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 6:67-78 (Pubitemid 350286221)
143. Filler SG, Sheppard DC (2006) Fungal invasion of normally non-phagocytic host cells. PLoS Pathog 2:e129
144. Lu Y, Li J, Yu H, Xu X, Liang J, Tian Y, Ma D, Lin G, Huang G, Lai R (2006) Two families of antimicrobial peptides with multiple functions from skin of rufous-spotted torrent frog, Amolops loloensis. Peptides 27:3085-3091 (Pubitemid 44738186)
145. Ali MF, Lips KR, Knoop FC, Fritzsch B, Miller C, Conlon JM (2002) Antimicrobial peptides and protease inhibitors in the skin secretions of the crawfish frog, Rana areolata. Biochim Biophys Acta 1601:55-63 (Pubitemid 38234531)
146. Conlon J (2006) The temporins. In: Kastin AJ (ed) Handbook of biologically active peptides. Elsevier, San Diego, pp 305-309
147. Conlon JM, Sonnevend A, Patel M, Davidson C, Nielsen PF, Pal T, Rollins-Smith LA (2003) Isolation of peptides of the brevinin-1 family with potent candidacidal activity from the skin secretions of the frog Rana boylii. J Pept Res 62:207-213 (Pubitemid 37338831)
148. Halverson T, Basir YJ, Knoop FC, Conlon JM (2000) Purification and characterization of antimicrobial peptides from the skin of the North American green frog Rana clamitans. Peptides 21:469-476 (Pubitemid 30261563)
149. Ali MF, Knoop FC, Vaudry H, Conlon JM (2003) Characterization of novel antimicrobial peptides from the skins of frogs of the Rana esculenta complex. Peptides 24:955-961 (Pubitemid 37130166)
150. Conlon JM, Al-Kharrge R, Ahmed E, Raza H, Galadari S, Condamine E (2007) Effect of aminoisobutyric acid (Aib) substitutions on the antimicrobial and cytolytic activities of the frog skin peptide, temporin-1DRa. Peptides 28:2075-2080 (Pubitemid 47419107)
151. Kim JB, Halverson T, Basir YJ, Dulka J, Knoop FC, Abel PW, Conlon JM (2000) Purification and characterization of antimicrobial and vasorelaxant peptides from skin extracts and skin secretions of the North American pig frog Rana grylio. Regul Pept 90:53-60 (Pubitemid 30331010)
152. Zhou J, McClean S, Thompson A, Zhang Y, Shaw C, Rao P, Bjourson AJ (2006) Purification and characterization of novel antimicrobial peptides from the skin secretion of Hylarana guentheri. Peptides 27:3077-3084 (Pubitemid 44738176)
153. Conlon JM, Coquet L, Leprince J, Jouenne T, Vaudry H, Kolodziejek J, Nowotny N, Bevier CR, Moler PE (2007) Peptidomic analysis of skin secretions from Rana heckscheri and Rana okaloosae provides insight into phylogenetic relationships among frogs of the Aquarana species group. Regul Pept 138:87-93 (Pubitemid 46054221)
154. Goraya J, Wang Y, Li Z, O'Flaherty M, Knoop FC, Platz JE, Conlon JM (2000) Peptides with antimicrobial activity from four different families isolated from the skins of the North American frogs Rana luteiventris, Rana berlandieri and Rana pipiens. Eur J Biochem 267:894-900 (Pubitemid 30082404)
155. Rollins-Smith LA, Doersam JK, Longcore JE, Taylor SK, Shamblin JC, Carey C, Zasloff M (2002) Antimicrobial peptide defenses against pathogens associated with global amphibian declines. Dev Comp Immunol 26:63-72 (Pubitemid 33010815)
156. Kim JB, Iwamuro S, Knoop FC, Conlon JM (2001) Antimicrobial peptides from the skin of the Japanese mountain brown frog, Rana ornativentris. J Pept Res 58:349-356 (Pubitemid 33095973)
157. Bevier CR, Sonnevend A, Kolodziejek J, Nowotny N, Nielsen PF, Conlon JM (2004) Purification and characterization of antimicrobial peptides from the skin secretions of the mink frog (Rana septentrionalis). Comp Biochem Physiol C Toxicol Pharmacol 139:31-38 (Pubitemid 39535785)
158. Conlon JM, Sonnevend A, Patel M, Camasamudram V, Nowotny N, Zilahi E, Iwamuro S, Nielsen PF, Pal T (2003) A melittin-related peptide from the skin of the Japanese frog, Rana tagoi, with antimicrobial and cytolytic properties. Biochem Biophys Res Commun 306:496-500 (Pubitemid 36683101)
159. Conlon JM, Abraham B, Sonnevend A, Jouenne T, Cosette P, Leprince J, Vaudry H, Bevier CR (2005) Purification and characterization of antimicrobial peptides from the skin secretions of the carpenter frog Rana virgatipes (Ranidae, Aquarana). Regul Pept 131:38-45 (Pubitemid 41392990)
160. Chen T, Zhou M, Rao P, Walker B, Shaw C (2006) The Chinese bamboo leaf odorous frog (Rana (Odorrana) versabilis) and North American Rana frogs share the same families of skin antimicrobial peptides. Peptides 27:1738-1744 (Pubitemid 43866294)